GlobalData on MSN
GSK forges pact with Empirico for respiratory siRNA in $745m deal
GSK now owns the global development and commercialisation rights to Empirico's COPD-targeting (siRNA) oligonucleotide, ...
Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...
Q3 2025 Earnings Call Transcript October 29, 2025 GSK plc beats earnings expectations. Reported EPS is $1.48, expectations ...
GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...
Cash generated from operations totaled £2.5 billion, with free cash flow of £1.2 billion. GSK declared a dividend of 16 pence ...
MedPage Today on MSN
Adverse Event Risks Vary Among Asthma Biologics, FDA Data Show
CHICAGO -- Adverse event risks varied across biologics used by asthma patients, an analysis of data submitted to the FDA ...
GSK raised its full-year guidance on Wednesday, after delivering stronger-than-expected third-quarter results, driven by ...
Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...
Cash generated from operations totaled £2.5 billion, with free cash flow of £1.2 billion. GSK declared a dividend of 16 pence ...
New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.
GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback